Literature DB >> 25883197

Altered intestinal microbial flora and impaired epithelial barrier structure and function in CKD: the nature, mechanisms, consequences and potential treatment.

Nosratola D Vaziri1, Ying-Yong Zhao1, Madeleine V Pahl1.   

Abstract

Chronic kidney disease (CKD) results in systemic inflammation and oxidative stress which play a central role in CKD progression and its adverse consequences. Although many of the causes and consequences of oxidative stress and inflammation in CKD have been extensively explored, little attention had been paid to the intestine and its microbial flora as a potential source of these problems. Our recent studies have revealed significant disruption of the colonic, ileal, jejunal and gastric epithelial tight junction in different models of CKD in rats. Moreover, the disruption of the epithelial barrier structure and function found in uremic animals was replicated in cultured human colonocytes exposed to uremic human plasma in vitro We have further found significant changes in the composition and function of colonic bacterial flora in humans and animals with advanced CKD. Together, uremia-induced impairment of the intestinal epithelial barrier structure and function and changes in composition of the gut microbiome contribute to the systemic inflammation and uremic toxicity by accommodating the translocation of endotoxin, microbial fragments and other noxious luminal products in the circulation. In addition, colonic bacteria are the main source of several well-known pro-inflammatory uremic toxins such as indoxyl sulfate, p-cresol sulfate, trimethylamine-N-oxide and many as-yet unidentified retained compounds in end-stage renal disease patients. This review is intended to provide an overview of the effects of CKD on the gut microbiome and intestinal epithelial barrier structure and their role in the pathogenesis of systemic inflammation and uremic toxicity. In addition, potential interventions aimed at mitigating these abnormalities are briefly discussed.
© The Author 2015. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.

Entities:  

Keywords:  cardiovascular disease; end-stage renal disease; microbiome; oxidative stress; uremia

Mesh:

Year:  2015        PMID: 25883197     DOI: 10.1093/ndt/gfv095

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  112 in total

Review 1.  Probiotics and chronic kidney disease.

Authors:  Laetitia Koppe; Denise Mafra; Denis Fouque
Journal:  Kidney Int       Date:  2015-09-16       Impact factor: 10.612

2.  Effect of Synbiotic Therapy on Gut-Derived Uremic Toxins and the Intestinal Microbiome in Patients with CKD.

Authors:  Nosratola D Vaziri
Journal:  Clin J Am Soc Nephrol       Date:  2016-01-15       Impact factor: 8.237

Review 3.  Resistant starch for modulation of gut microbiota: Promising adjuvant therapy for chronic kidney disease patients?

Authors:  Cristiane Moraes; Natália A Borges; Denise Mafra
Journal:  Eur J Nutr       Date:  2016-01-30       Impact factor: 5.614

4.  Blood Microbiome Profile in CKD : A Pilot Study.

Authors:  Neal B Shah; Andrew S Allegretti; Sagar U Nigwekar; Sahir Kalim; Sophia Zhao; Benjamin Lelouvier; Florence Servant; Gloria Serena; Ravi Ishwar Thadhani; Dominic S Raj; Alessio Fasano
Journal:  Clin J Am Soc Nephrol       Date:  2019-04-08       Impact factor: 8.237

5.  Indoxyl sulfate associates with cardiovascular phenotype in children with chronic kidney disease.

Authors:  Johannes Holle; Uwe Querfeld; Marietta Kirchner; Alexandros Anninos; Jürgen Okun; Daniela Thurn-Valsassina; Aysun Bayazit; Ana Niemirska; Nur Canpolat; Ipek Kaplan Bulut; Ali Duzova; Ali Anarat; Rukshana Shroff; Yelda Bilginer; Salim Caliskan; Cengiz Candan; Jerome Harambat; Zeynep Birsin Özcakar; Oguz Soylemezoglu; Sibylle Tschumi; Sandra Habbig; Ebru Yilmaz; Ayse Balat; Aleksandra Zurowska; Nilgun Cakar; Birgitta Kranz; Pelin Ertan; Anette Melk; Karolis Azukaitis; Franz Schaefer
Journal:  Pediatr Nephrol       Date:  2019-08-19       Impact factor: 3.714

6.  Blood Microbiome in CKD: Should We Care?

Authors:  Robert D Mair; Tammy L Sirich
Journal:  Clin J Am Soc Nephrol       Date:  2019-04-08       Impact factor: 8.237

7.  Macrophages Are Involved in Gut Bacterial Translocation and Reversed by Lactobacillus in Experimental Uremia.

Authors:  Lingshuang Sun; Hua Liu; Hongli Jiang; Meng Wei; Shanshan Liang; Meng Wang; Kehui Shi; Quan He
Journal:  Dig Dis Sci       Date:  2015-10-30       Impact factor: 3.199

8.  Gut Microbiota and Cardiometabolic Risk Factors in Hemodialysis Patients: A Pilot Study.

Authors:  Annabel Biruete; Jacob M Allen; Brandon M Kistler; Jin Hee Jeong; Peter J Fitschen; Kelly S Swanson; Kenneth R Wilund
Journal:  Top Clin Nutr       Date:  2019 Apr-Jun       Impact factor: 0.508

Review 9.  The crosstalk of gut microbiota and chronic kidney disease: role of inflammation, proteinuria, hypertension, and diabetes mellitus.

Authors:  Mehmet Kanbay; Emine M Onal; Baris Afsar; Tuncay Dagel; Aslihan Yerlikaya; Adrian Covic; Nosratola D Vaziri
Journal:  Int Urol Nephrol       Date:  2018-05-04       Impact factor: 2.370

10.  Measurement of the intestinal permeability in chronic kidney disease.

Authors:  Matty L Terpstra; Ramandeep Singh; Suzanne E Geerlings; Frederike J Bemelman
Journal:  World J Nephrol       Date:  2016-07-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.